AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04395248
Drug: Type of volatile anesthetics and M-Entropy guidance of anesthesia depth
RxNorm normalized name: Betagen brand of Betamethasone and Gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the operating room, a M-Entropy™ sensor and S/5™ module (GE Healthcare, Helsinki, Finland) will be applied to all patients' forehead before induction of anesthesia according to the manufacturer's recommendations. Patients will be randomized to Sevoflurane or Desflurane as the single volatile anesthetics for general anesthesia.~Besides, patients will be randomized to M-Entropy group or controls. In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the Response and State Entropy value between 40 and 60 from the start of anesthesia to the end of surgery. In the usual care group, dosage of volatile anesthetics will be titrated according to clinical judgment. M-Entropy monitoring will be continued in the usual care group, but the Entropy number and EEG waveform will be concealed from the anesthetist in charge.
Trial: NCT02965664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drops contain the same ingredients as PresbiDrops except for the active ingredients
Trial: NCT04316325
Drug: Medical abortion
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trained abortion providers will counsel participants about medical abortion via videoconference or telephone, the abortion medications will be sent to the participants via mail or will be accessed at a pharmacy, the provider will follow up one week later with the participants to assess outcomes, and four weeks later the participant will take a pregnancy test to confirm completion of the abortion
Trial: NCT01520545
Drug: Gablofen® 3 mg/mL (baclofen injection)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a prospective twelve-month Phase IIIb clinical safety trial followed by a 2-year, Phase IV study that will be conducted at clinical trial sites that are experienced with the use of intrathecal baclofen. Patients will be followed for the duration of their treatment with Gablofen® (baclofen injection) 3 mg/mL using the SynchroMed® II Programmable Pump or until the study is terminated.
Trial: NCT01494103
Drug: AP1903
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP1903 will be administered if there is development of Grade 1 or greater GvHD.~Dose: 0.4 mg/kg by IV over 2 hours.~Up to 3 additional doses may be administered if the GvHD does not respond or gets worse.
Trial: NCT02293460
Drug: I10E
RxNorm normalized name: SET,INFUSION ACCU-CHEK ULTRAFLEX-I10-110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who meet all eligibility criteria will receive one dose of IMP at 2g/kg over 2-5 days followed by 7 doses of IMP at 1g/kg over 1-2 day(s), every 3 weeks.~Duration of treatment period: 21 weeks +/- 7 days.
Trial: NCT01185860
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral doses
Trial: NCT02145624
Drug: Repevax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaccine
Trial: NCT00354562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 14 days every 21 days
Trial: NCT01074008
Drug: ABT-450
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg capsules co-administered with ritonavir
Trial: NCT01074008
Drug: ABT-333
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg tablet
Trial: NCT01665651
Drug: Yougui granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yougui granules is traditional Chinese patent medicine used to treatment patients with kidney Yang deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
Trial: NCT01665651
Drug: Zuogui granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zuogui granules is traditional Chinese patent medicine used to treatment patients with kidney Yin deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
Trial: NCT01665651
Drug: Yougui granules placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
Trial: NCT01665651
Drug: Zuogui granules placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
Trial: NCT03577886
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate Buffer Diluent oral solution
Trial: NCT02121041
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 12.5 mg or 25 mg
Trial: NCT02788513
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01577056
Drug: HMG Coenzyme reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All FH subjects are on standard statin treatment during study period
Trial: NCT03907241
Drug: Octanorm 16.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human normal immunoglobulin
Trial: NCT03018509
Drug: JTE-451
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug tablets containing JTE-451
Trial: NCT01280344
Drug: Saline Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV)
Trial: NCT02938442
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
Trial: NCT03018509
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets identical in appearance to the active drug tablets
Trial: NCT02938442
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
Trial: NCT00005094
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01730040
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin over-encapsulated tablets orally.
Trial: NCT01730040
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for alirocumab and ezetimibe.
Trial: NCT02854696
Drug: best medical care
RxNorm normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will continue their insulin treatment
Trial: NCT03449199
Drug: TMX-049
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A certain dose of TMX-049 to be taken orally, once daily
Trial: NCT03449199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to be taken orally, once daily
Trial: NCT01385826
Drug: Anti-tumor necrosis factor alpha monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of adalimumab will be 40 mg for children age 13 and over and for children younger than 13 adalimumab 24 mg per m2 BSA (up to a maximum total body dose of 40 mg).
Trial: NCT01385826
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 4 injections of placebo on D0, D14, D28, and D42 with assessment of the primary endpoint at M2
Trial: NCT02622659
Drug: Fuganlin Oral Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: less than 1 years old: 5mL each time and three times a day~1\~3 years old: 10mL each time and three times a day~4\~6 years old: 10mL each time and four times a day~7\~12 years old: 10mL each time and five times a day
Trial: NCT02622659
Drug: Xiaoer Jiebiao Oral Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1\~2 years old: 5mL each time and twice a day~3\~5 years old: 5mL each time and three times a day~6\~14 years old: 10mL each time and twice a day
Trial: NCT00035321
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00666887
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg twice daily to be taken for up to 2 years
Trial: NCT00666887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo twice daily for 2 years
Trial: NCT02588820
Drug: Antiretroviral Therapy (Experimental)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Initial ART until HLA-B5701 results became available (48 hours):~   1. Tenofovir 245 mg once a day~  2. Emtricitabine 200 mg once a day~  3. Dolutegravir 50 mg once a day~  4. Darunavir 800 mg once a day~  5. Ritonavir 100 mg once a day~  6. Maraviroc 150 mg twice a day~2. Three months continuation treatment (after HLA-B5701 confirmed as negative):~   1. Dolutegravir 50 mg once a day.~  2. Abacavir 600 mg once a day~  3. Lamivudine 300 mg once a day~  4. Darunavir 800 mg once a day~  5. Ritonavir 100 mg once a day~  6. Maraviroc 150 mg twice a day The whole treatment schedule comprises 7 pills per day (in a single dose), except for maraviroc, which will be given twice daily.~3. Nine months continuation treatment (till complete 12 months treatment):~   1. Abacavir, 600mg once a day~  2. Lamivudine, 300 mg once a day~  3. Dolutegravir, 50 mg once a day
Trial: NCT01701973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During Aim 1, given on one of two study days (other study day subjects receive sitagliptin.) During Aim 2, given on one of two study days (other study day subjects receive either L-NMMA, pegvisomant, or Exendin 9-39 pending their group assignment)
Trial: NCT02904538
Drug: isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01677208
Drug: Danhong injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower. 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
Trial: NCT01677208
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
Trial: NCT03808740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill
Trial: NCT00471991
Drug: Ethinyl estradiol / dienogest (SH D00659 AF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.Volunteers have to undergo a series of blood sampling during the 2nd treatment cycle to evaluate the pharmacokinetic (liberation, absorption, distribution, metabolization and excretion) of the new oral contraceptive.
Trial: NCT02363439
Drug: IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMO-8400 at 0.6 mg/kg/wk or 1.2 mg/kg twice weekly as defined per Protocol 8400-401
Trial: NCT02023840
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00551616
Drug: CDB-2914
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT03946917
Drug: JS001
RxNorm normalized name: Janus Kinase Inhibitor JS001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS001 3 mg/kg, iv drip, d1, d15, q4w
Trial: NCT01854255
Drug: doxorubicin and cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxorubicin and cisplatin as intraperitoneal chemotherapy
Trial: NCT02010255
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDV/SOF FDC tablet administered orally once daily
Trial: NCT01134627
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants who are self-administering Rebif® (IFN beta-1a) 44 microgram (mcg) as subcutaneous (sc) injection thrice weekly will also receive minocycline 100 milligram (mg) tablet twice daily as an add-on therapy in accordance with clinical practice for 96 weeks.
Trial: NCT01134627
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who are self-administering Rebif® (IFN beta-1a) 44 mcg as sc injection thrice weekly will also receive placebo tablets twice daily for 96 weeks.
Trial: NCT00508027
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of 3 dosages of simvastatin given in a dose-escalating fashion. 20 mg, 40 mg, or 80 mg PO QD x 21 days followed by a drug taper x 4 days.
Trial: NCT01275157
Drug: LY2452473
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as a liquid suspension
Trial: NCT03668431
Drug: PDR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDR001 will be administered IV every 28 days
Trial: NCT00977431
Drug: BIBW2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating dose cohorts during Radiotherapy(RT) period, fixed dose after RT
Trial: NCT00977431
Drug: BIBW2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating dose cohorts during Radiotherapy(RT) period , fixed dose after RT
Trial: NCT05369091
Drug: Simvastatin 10mg
RxNorm normalized name: SIMVASTATIN 10MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atraumatic Extraction and administration of SIM (10 mg tablet grounded and added with normal saline, with gelatin sponge as a transporter) into the socket to observe alveolar bone healing.
Trial: NCT01876368
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01876368
Drug: Placebo of LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01391845
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo orally in a unique dose the day of hCG injection
Trial: NCT02563769
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally in capsules identical to CLAV and be filled with crystalline microcellulose
Trial: NCT02078921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00689845
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00689845
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00689845
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00689845
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01661634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00656968
Drug: 10-day sequential treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: esomeprazole (40 mg daily) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, metronidazole (500 mg, bid) from day 6 to day 10
Trial: NCT00656968
Drug: 10-day concomitant therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: esomeprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 10, clarithromycin (500 mg, bid) from day 1 to day 10, metronidazole (500 mg, bid) from day 1 to day 10
Trial: NCT01246713
Drug: Acetaminophen solid formulation
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
Trial: NCT04686994
Drug: ASC 41 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT00190489
Drug: AC (ADM 40mg/m2+CPA 500mg/m2) q21 days x 6 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00115024
Drug: Micronized 17B-estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02079337
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00109486
Drug: GW685698X
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00932724
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampoules with 1 ml placebo solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
Trial: NCT00707421
Drug: ketorolac acetate
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01168687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04628936
Drug: KZR-616
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous 30 mg for 1 week, then 45 mg weekly
Trial: NCT01118026
Drug: BEACOPP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bleomycin 10 units/m\^2 IV on Day 8 etoposide 200 mg/m\^2 IV on Days 1, 2 and 3 doxorubicin 35 mg/m\^2 IV on Day 1 cyclophosphamide 1250 mg/m\^2 IV on Day 1 vincristine 1.4 mg/m\^2 IV on Day 8 procarbazine 100 mg/m\^2 orally on Days 1-7 prednisone 40 mg/m\^2 orally on Days 1-14
Trial: NCT00148720
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taken orally twice a day for 14 days and treatment will repeat every 21 days (1 cycle) for 4 cycles
Trial: NCT06677853
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were applied with placebo at the affected area 3 times a day for 24 weeks.
Trial: NCT04253353
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg tablet
Trial: NCT00648245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given once daily for 21 days by nebulizer
Trial: NCT01471834
Drug: Medical Management
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05149924
Drug: QL1012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection,starting dose within 75IU \~ 300IU determined by the age , maximum daily dose 450IU
Trial: NCT05149924
Drug: Gonal-f ®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection,starting dose within 75IU \~ 300IU determined by the age , maximum daily dose 450IU
Trial: NCT03965728
Drug: BAY1830839
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral.
Trial: NCT03965728
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral.
Trial: NCT03965728
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Only for Dose 3 step. Tablet, oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2.
Trial: NCT01478828
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral qd varying dose escalations/de-escalations
Trial: NCT01789957
Drug: AC2993
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-Week transition of AC2993 5 mcg subcutaneously injected twice daily followed by an open-ended period through study termination (up to 52 weeks) of AC2993 10 mcg subcutaneously injected twice daily
Trial: NCT02265406
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01961882
Drug: OCV-501
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01961882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00715091
Drug: diclophenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous (daily) treatment of diclofenac cholestyramine 150 mg, divided into 75mg twice daily
Trial: NCT00715091
Drug: diclophenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg daily
Trial: NCT04493476
Drug: Chinese herbal formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal formula
Trial: NCT04664816
Drug: Placebo Treatment
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally, twice a day for at least 12 months.